16 results about "Suprachoroidal space" patented technology

The invention relates to an injector adapter, an injection assembly and a using method. The injector adapter comprises a connecting piece, and a cavity is formed in the connecting piece; the guide pipe penetrates through the connecting piece and penetrates through the cavity, and the pipe wall, located in the cavity, of the guide pipe is provided with a penetrating channel; the elastic sheath is located in the cavity, the elastic sheath is arranged outside the catheter in a sleeving mode, a potential gap cavity is formed between the elastic sheath and the catheter, and the potential gap cavity is in fluid communication with the catheter through the penetrating channel. The injector adapter can be used in cooperation with an existing injector, so that an operator can more visually judge whether a needle head penetrates through the sclera to reach the suprachoroidal space or not so as to guide the operator to conduct medicine injection, and the injection convenience of the operator is remarkably improved.

The present disclosure provides methods for administering formulations to the suprachoroidal space of the eye to achieve targeted drug delivery to a desired site of action within the eye. The methods include using a pushing formulation that includes a material such as a gel that expands due to physiochemical cues; or using an electric field to affect the movement of a formulation within the suprachoroidal space; or a combination of a pushing formulation with an electric field.

An ocular access instrument (20) includes an attachment assembly (32) configured to engage a sclera of an eye, and an actuator assembly (34) configured to bear against the sclera. When the attachment assembly engages the sclera, movement of the actuator assembly inwardly against the eye displaces the choroid from the sclera, thereby creating an enlarged suprachoroidal space. The ocular access instrument may also include a needle guide (40) configured to receive the needle and guide the needle into the enlarged suprachoroidal space.

This invention discloses an implantable stent for aqueous humor drainage in glaucoma, belonging to the field of ophthalmic implantable medical devices. The stent comprises a flexible tubular body, a passive pressure regulating valve, a pressure response module, an anchoring structure, a variable-diameter main drainage channel, a porous diffuse diversion structure at the tail, and a surface functionalized layer. The inflow end is placed in the anterior chamber or anterior chamber angle, and the outflow end is placed in the suprachoroidal space. When the pressure difference between the inflow and outflow ends reaches a preset threshold, the pressure valve opens, allowing aqueous humor to be uniformly introduced into the suprachoroidal space through the main channel and the porous diversion structure; when the pressure difference is below the threshold, the valve closes, limiting excessive drainage. The anchoring structure fixes the stent's position and prevents displacement. This invention achieves effective aqueous humor drainage while reducing the risk of excessive drainage, and improves the stent's implantation stability, drainage uniformity, and long-term follow-up evaluation capabilities.

A triamcinolone acetonide pharmaceutical composition and a preparation method therefor. The pharmaceutical composition contains the following ingredients: (i) a triamcinolone acetonide active ingredient, (ii) hyaluronic acid or a salt thereof. (iii) a buffering agent; and (iv) a tonicity adjustment agent. The pharmaceutical composition has a suitable viscosity, osmotic pressure and particle size range and is easily injected, especially administrated by means of a suprachoroidal space injection.

Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

An ocular implant system is described herein in which an implant (200) is deployed in the posterior space of an eye - e.g., the suprachoroidal space or the subconjunctival space or the intrascleral space - through an access in the anterior chamber (160) for reducing intraocular pressure in the eye. The shunt device (200) is implanted using an implantation device that includes a hollow shaft (330) mounted on a fixed shaft (320). The shunt device (200) is located in the distal end of the hollow shaft (330) and adjacent to the distal end of the fixed shaft (320) at a location behind the distal end of the hollow shaft. Once the distal end of the hollow shaft (330) and the shunt device (200) are at the desired depth within the posterior space, the hollow shaft is withdrawn over the fixed shaft through the access in the anterior chamber (160) towards the proximal end of the fixed shaft, leaving the shunt device in the posterior space.

A stent implant for treating glaucoma by intraocular fluid drainage from the anterior chamber, for example into the suprachoroidal space. The stent implant is designed to change in shape after being inserted into the eye, during which change the width and / or thickness or the flow cross-section is increased by for example 20%, in another example more than 200%, and in a further example by more than 400%, at least one point of the stent implant. In the case of intraocular fluid drainage from the anterior chamber into the suprachoroidal space, a cyclodialysis cleft which may open can be largely or completely closed. With appropriate adjustments, the stent implant can also be applied in trabecular, uveoscleral, uveolymphatic and subconjunctival applications for intraocular fluid drainage from the anterior chamber. The implant can even be used for direct intraocular fluid discharge from the anterior chamber onto the surface of the eye.

This disclosure generally relates to the field of ophthalmic therapies, and more particularly to the treatment of various eye diseases and conditions by the non-surgical administration into a subject's eye of a pharmacological composition described herein containing a plasma kallikrein inhibitor. Avoralstat is included among the plasma kallikrein inhibitors. The compositions and methods include the administration of a plasma kallikrein inhibitor into the suprachoroidal space (SCS) of the eye.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

This invention relates to the field of biotechnology and discloses a method for screening drugs capable of preventing and / or treating posterior segment diseases of the eye. The method includes: first, decompressing the anterior chamber of an experimental animal; then, pre-establishing a "perforation-closure" channel in the sclera of the experimental animal; next, injecting the drug to be screened into the suprachoroidal space of the experimental animal through the "perforation-closure" channel in the sclera; and finally, evaluating the effectiveness of the drug in preventing and / or treating posterior segment diseases based on changes in the eye condition of the experimental animal. This invention reduces the incidence of ocular surface inflammation and improves safety by lowering intraocular pressure and creating a pre-closed scleral incision to prevent backflow of the injected AAV vector; it also provides a broader expression range and longer duration of action. Studies have shown that injecting shRNA targeting the TGF-β2 gene using the method of this invention inhibits myopia progression in a guinea pig model. The method provided by this invention is beneficial for screening gene therapy drugs related to posterior segment diseases.

The disclosure relates to ophthalmic implants, specifically a flexible, self-expanding spacer device deployable in subconjunctival, sub-Tenon's, or suprachoroidal spaces to manage intraocular fluids. The device addresses limitations of fixed-resistance drainage and fibrosis-related failure in glaucoma surgery by maintaining a controlled three-dimensional reservoir (bleb space) for aqueous humor outflow while minimizing tissue trauma. In one aspect, a shape-memory body transitions from a compressed, delivery-compatible state to an expanded configuration defining a convex internal volume, optionally with collapse-resistant reinforcements and tissue-engaging elements for atraumatic stabilization. Preferred embodiments include anterior relief geometry to avoid corneal contact and posterior flow-directing features to promote posterior bleb formation and uniform pressure control. A delivery member with a reduced-profile, tapered piercing tip and optional bent shaft enables minimally invasive ab externo implantation and controlled, coaxial deployment. Advantages include streamlined single-step delivery, stable long-term bleb architecture, reduced hypotony and fibrotic encapsulation, and compatibility with trabeculectomy and shunt-based outflow.

Ocular implants, kits and methods are disclosed. In one arrangement, an implant comprises a frame deployable in the suprachoroidal space of an eye and configured to resiliently adopt an arched elongate shape to promote drainage of aqueous humor through the suprachoroidal space when the frame is deployed in the suprachoroidal space. Relative to an axis of elongation of the elongate shape: the frame has a first axial end and a second axial end; and the arched elongate shape defines a channel. The channel has a first axial opening at the first axial end of the frame, a second axial opening at the second axial end of the frame, and a longitudinal opening extending continuously from the first axial end to the second axial end.

This disclosure is generally in the field of ophthalmic therapies, and more particularly to the treatment of various ocular diseases and conditions by non-surgical administration to the eye of a subject of a drug composition described herein containing a plasma kallikrein inhibitor. Plasma kallikrein inhibitors include avoralstat. The compositions and methods include delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye.

Minimally invasive, implantable ophthalmic drainage devices and systems for delivering the drainage devices are disclosed. The disclosed drainage devices may allow more stable implantation in the suprachoroidal space of an eye and control of fluid drainage from the eye for treating glaucoma. The disclosed delivery systems may improve control and reduce difficulty of device implantation.

Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.